$PVCT Provectus Biopharmaceuticals, Inc. (NYSE VCT
Post# of 108
(Total Views: 571)
Posted On: 03/21/2017 9:11:10 AM
$PVCT Provectus Biopharmaceuticals, Inc. (NYSE VCT): Estimates, Ratings, and Insiders Point the Way1-1.jpg
Provectus Biopharmaceuticals, Inc. (NYSE VCT) stock is currently pricing at roughly $0.03. Our analysis shows that the stock is widely covered by equity research firms, and target prices are revealing. From a summary standpoint, we track the median one-year price target among 1 analysts covering the company at $3.50. That suggests shares of the stock may have another 99 percent to the upside left to run. Of those analysts we surveyed, the highest price target on recordsits at $3.50, which would imply another -11467 percent in upside potential. If we look for a little more qualitative data on the range of expectations, we find in analyst notes that the stock has 0 “Buy” ratings in place. At the same time, 0 rate the stock a “strong buy”, suggesting more conviction in the story. As for the doubters, 0 equity research analyst firms call this stock a “Hold” and 0 consider it bad enough to warrant a “Sell” rating.
Analysts at Rodman & Renshaw took a look at PVCT shares in a research note released on Apr 07, 2009, and issued a Mkt Outperform rating to this company. Rodman & Renshaw analysts provided their own take on company recently as well. In a research note published on Nov 27, 2007,the house assigned a Mkt Perform rating to this stock.
Provectus Biopharmaceuticals, Inc. (PVCT) Cap Table Analysis
Breaking down the capitalization table is our next goal. From a bird’s eye view, Executives hold 8.12 percent of the stock.
If we take a more granular look, Kenneth D Lewis is one of the largest owners in company capital stock among insiders. According to U.S. Securities and Exchange Commission (SEC) filings, this investor owns 5,714,183 shares, representing a total current market value of roughly $171425.49. Kelly Adams is another major player among company insiders, currently holding 5,526,123 shares as of 2.27%, carrying a current market value of $165783.69. Timothy C. Scott,PhD is currently ranked as the number three insider in terms of representation on the cap table for the stock, holding 1,521,845 shares, valued at around $45655.35 as of recent close.
Provectus Biopharmaceuticals, Inc. (NYSE VCT) stock is currently pricing at roughly $0.03. Our analysis shows that the stock is widely covered by equity research firms, and target prices are revealing. From a summary standpoint, we track the median one-year price target among 1 analysts covering the company at $3.50. That suggests shares of the stock may have another 99 percent to the upside left to run. Of those analysts we surveyed, the highest price target on recordsits at $3.50, which would imply another -11467 percent in upside potential. If we look for a little more qualitative data on the range of expectations, we find in analyst notes that the stock has 0 “Buy” ratings in place. At the same time, 0 rate the stock a “strong buy”, suggesting more conviction in the story. As for the doubters, 0 equity research analyst firms call this stock a “Hold” and 0 consider it bad enough to warrant a “Sell” rating.
Analysts at Rodman & Renshaw took a look at PVCT shares in a research note released on Apr 07, 2009, and issued a Mkt Outperform rating to this company. Rodman & Renshaw analysts provided their own take on company recently as well. In a research note published on Nov 27, 2007,the house assigned a Mkt Perform rating to this stock.
Provectus Biopharmaceuticals, Inc. (PVCT) Cap Table Analysis
Breaking down the capitalization table is our next goal. From a bird’s eye view, Executives hold 8.12 percent of the stock.
If we take a more granular look, Kenneth D Lewis is one of the largest owners in company capital stock among insiders. According to U.S. Securities and Exchange Commission (SEC) filings, this investor owns 5,714,183 shares, representing a total current market value of roughly $171425.49. Kelly Adams is another major player among company insiders, currently holding 5,526,123 shares as of 2.27%, carrying a current market value of $165783.69. Timothy C. Scott,PhD is currently ranked as the number three insider in terms of representation on the cap table for the stock, holding 1,521,845 shares, valued at around $45655.35 as of recent close.
(0)
(0)Provectus Biopharmaceuticals Inc. (PVCT) Stock Research Links
Here We Go!!!!